H型高血压合并冠心病患者血浆非对称性二甲基精氨酸与同型半胱氨酸的相关性

刘美玲; 崔建国; 王树娟; 黄丽; 杨倩倩; 齐洁; 徐文文; 张清潭

doi:10.13201/j.issn.1001-1439.2017.08.005

H型高血压合并冠心病患者血浆非对称性二甲基精氨酸与同型半胱氨酸的相关性

- 滨州医学院附属医院老年医学科(山东滨州, 256600)

详细信息

通讯作者: 张清潭,E-mail:qtzhangby@126.com

中图分类号: R544.1

收稿日期: 2017-03-08

Association between plasma homocysteine level and plasma asymmetric dimethylarginine level in H-type hypertension patients with coronary heart disease

- Department of Geriatrics, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, 256600, China

More Information

Corresponding author: ZHANG Qingtan, E-mail: qtzhangby@126.com

Received Date: 08 March 2017

摘要

摘要: 目的:探讨H型高血压合并冠心病患者血浆非对称性二甲基精氨酸(ADMA)水平与血浆同型半胱氨酸(Hcy)水平的相关性。方法:选择2016-01-2016-11于我院住院的原发性高血压病患者222例(其中单纯高血压病组66例,高血压合并冠心病组156例),采用酶联免疫吸附法检测血浆ADMA、Hcy水平。根据血浆Hcy水平,将单纯高血压组分为H型高血压亚组46例和非H型高血压亚组20例;将高血压合并冠心病组进一步分为H型高血压合并冠心病亚组104例、非H型高血压合并冠心病亚组52例。比较各组血浆ADMA水平,分析血浆ADMA与Hcy的相关性。结果:高血压合并冠心病组血浆ADMA、Hcy水平均高于单纯高血压组。H型高血压亚组血浆ADMA、Hcy水平高于非H型高血压亚组,H型高血压合并冠心病亚组血浆ADMA、Hcy水平高于非H型高血压合并冠心病亚组,差异有统计学意义(P<0.05);线性相关分析显示,高血压合并冠心病患者血浆ADMA与Hcy水平有相关性(r=0.76,P<0.01);进一步多元逐步回归分析显示,血浆Hcy是ADMA的影响因素。结论:H型高血压患者及H型高血压合并冠心病患者血浆Hcy、ADMA水平均高于非H型高血压患者及非H型高血压合并冠心病患者,高血压合并冠心病患者血浆ADMA水平与Hcy水平呈正相关。
- 高血压 /
- 冠心病 /
- 同型半胱氨酸 /
- 非对称性二甲基精氨酸
Abstract: Objective: To study the association between plasma homocysteine(Hcy) level and plasma asymmetric dimethylarginine(ADMA) in H-type hypertension patients with coronary heart disease. Method: Two hundred and twenty-two primary hypertensive patients admitted to our hospital from January 2016 to November 2016 were divided into hypertensive group(n=66) and hypertension with coronary heart disease group(n=156). The plasma ADMA and Hcy levels were detected by enzyme-linked immunosorbent assay. According to plasma homocysteine level, hypertension with coronary heart disease group was then divided into H-type hypertension with coronary heart disease group(n=104) and non H-type hypertension with coronary heart disease group(n=52). Their plasma ADMA levels were compared. The association between plasma Hcy level and plasma ADMA level was analyzed. Result: The plasma ADMA and Hcy levels were significantly higher in hypertension with coronary heart disease group than in hypertensive group and the plasma ADMA and Hcy levels was significantly higher in H-type hypertension group and H-type hypertension with coronary heart disease group than in non H-type hypertensive group and non H-type hypertension with coronary heart disease group(P<0.05). Linear correlation analysis showed that the plasma ADMA level was associated with the plasma Hcy level in hypertension with coronary heart disease group(r=0.76,P<0.01). Further multiple stepwise regression analysis showed that the plasma Hcy level influenced the plasma ADMA level. Conclusion: The plasma Hcy and ADMA levels were higher in H-type hypertensive patients and H-type hypertension patients with coronary heart disease than in non H-type hypertensive patients and non H-type hypertension patients with coronary heart disease. Plasma ADMA levels are positively correlated with Hcy levels in hypertension patients with coronary heart disease.
- Hypertension /
- Coronary heart disease /
- Homocysteine /
- Asymmetric dimethylarginine

HTML全文

参考文献(21)

[1]	胡大一, 徐希平.有效控制"H型"高血压——预防卒中的新思路[J].中华内科杂志, 2008, 47 (12):976-977.
[2]	GKALIAGKOUSI E, GAVRIILAKI E, TRIANTAFYLLOU A, et al.Clinical significance of endothelial dysfunction in essential hypertension[J].Curr Hypertens Rep, 2015, 17:85-86.
[3]	中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华高血压杂志, 2011, 19 (7):701-743.
[4]	COHEN E, LEVI A, VECHT-LIFSHITZ S E, et al.Assessment of a possible link between hyperhomocysteinemia and hyperuricemia[J].J Investig Med, 2015, 63:534-538.
[5]	VERDOIA M, SCHAFFER A, BARBIER L, et al.Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting[J].J Cardiovasc Med (Hagerstown), 2015, 16:100-105.
[6]	ARDUINO A, RICHARD J.Homocysteine and cardiovascular risk[J].JACC, 2011, 58:1034-1035.
[7]	李建平, 卢新政, 霍勇, 等.H型高血压诊断与治疗专家共识[J].中华高血压杂志, 2016, 24 (2):123-127.
[8]	SANTILLI F, DAVIOG, PATRONO C.Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis:A mechanistic and clinical perspective[J].Vascul Pharmacol, 2016, 78:1-9.
[9]	GIMBRONE M A JR, GARCÍA-CARDEÑA G.Endothelial cell dysfunction and the pathobiology of atherosclerosis[J].Circ Res, 2016, 118:620-636.
[10]	CAHILL P A, REDMOND E M.Vascular endothelium-Gatekeeper of vessel health[J].Atherosclerosis, 2016, 248:97-109.
[11]	BLACKWELL S.The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine[J].Ann Clin Biochem, 2010, 47 (Pt 1):17-28.
[12]	MARGARITIS M, CHANNON K M, ANTONIADES C.Statins as regulators of redox state in the vascular endothelium:beyond lipidlowering[J].Antioxid Redox Signal, 2014, 20:1198-1215.
[13]	PERTICONE F, SCIACQUA A, MAIO R, et al.Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension[J].J Am Coll Cardiol, 2005, 46:518-523.
[14]	JUONALA M, VIIKARI J S, ALFTHAN G, et al.Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study[J].Circulation, 2007, 116:1367-1373.
[15]	BOGER R H, SULLIVAN L M, SCHWEDHELM E, et al.Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community[J].Circulation, 2009, 119:1592-1600.
[16]	JUNG C S, WISPEL C, ZWECKBERGER K, et al.Endogenous nitric-oxide synthase inhibitor ADMA after acute brain injury[J].Int J Mol Sci, 2014, 15:4088-4103.
[17]	MORETTIN A, BALDWIN R M, COTE J.Arginine methyltransferases as novel therapeutic targets for breast cancer[J].Mutagenesis, 2015, 30:177-189.
[18]	LIU X, HOU L, XU D, et al.Effect of asymmetric dimethylarginine (ADMA) on heart failure development[J].Nitric Oxide, 2016, 54:73-81.
[19]	LEIPER J, NANDI M.The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis[J].Nat Rev Drug Discov, 2011, 10:277-291.
[20]	RICCIONI G, SCOTTI L, D'ORAZIO N, et al.ADMA/SDMA in elderly subjects with asymptomatic carotid atherosclerosis:values and site-specific association[J].Int J Mol Sci, 2014, 15:6391-6398.
[21]	ISLAR O O, BARUTCUOGLU B, KABAROGLU C, et al.Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases?[J].Clin Biochem, 2012, 45:1325-1330.